secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2026-08-10T20:05:52+00:00
Accession:  0001140361-26-032014
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 2.01, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal closes $375M cash-plus-stock acquisition of Kashiv BioSciences
---------------------------------------------------------------------

- Closed Aug 10, 2026; paid $375M cash plus 28,942,098 Class A shares (fractional adjustment).
- Sellers eligible for up to $350M in U.S. regulatory milestone payments for six Kashiv candidates.
- 12-year royalty tail: 25% of gross profits above hurdle amounts for certain products.
- Funded partly via new $350M incremental term loan from Bank of America under Amended Credit Agreement.
- Creates integrated global biosimilars platform; targets $300B+ biologics loss-of-exclusivity over next decade.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000114036126032014/0001140361-26-032014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000114036126032014/ef20079825_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-032014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer